Catalog No.
Product Name
Application
Product Information
Citations
-
mTOR Inhibitor
CC214-2 is a selective mTOR kinase inhibitor that targets both mTORC1 and mTORC2 pathways, affecting pS6 and pAktS473 signaling. This compound induces autophagy, making it a promising candidate for host-directed therapy in tuberculosis, demonstrating synergistic bactericidal effects that can shorten treatment duration. Additionally, CC214-2 has shown efficacy in inhibiting Rapamycin-resistant signaling and suppressing glioblastoma growth in vitro and in vivo, positioning it as a valuable tool in cancer research and infectious disease studies. -
mTOR Inhibitor
T133 is a potent ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR) with an IC50 of 0.34 nM and a Ki of 0.17 nM. It effectively suppresses the phosphorylation of downstream targets, including AKT, S6K1, and 4EBP1, leading to the inhibition of cancer cell proliferation and migration, induction of apoptosis, cell cycle arrest, and promotion of autophagy. T133 demonstrates significant antitumor efficacy in xenograft mouse models and serves as a valuable tool in cancer research, particularly for studies involving gastric and lung cancers. -
AMPK Activator/mTOR Inhibitor
OSU-53 is an orally active AMPK activator and a direct mTOR inhibitor, exhibiting an EC50 of 0.3 μM. This compound induces autophagy by facilitating the conversion of LC3 I to LC3 II and plays a crucial role in modulating energy homeostasis by downregulating fatty acid biosynthesis while enhancing oxidative metabolism through upregulation of PGC1α and NRF-1. OSU-53 demonstrates antitumor activity across various cancer models, including breast and thyroid cancers, making it a valuable tool for cancer research and metabolic studies. -
mTOR Inhibitor
4-FPBUA is a semisynthetic analog of usnic acid that functions as an inhibitor of mTOR. It enhances cellular autophagy and supports blood-brain barrier (BBB) integrity, facilitating the transport of Amyloid β (Aβ) across monolayer cell systems. This compound is of particular interest in Alzheimer's disease research due to its potential to reverse BBB disruption and promote neuroprotection. -
mTOR Inhibitor
3HOI-BA-01 is a potent mTOR inhibitor that plays a critical role in modulating cellular processes. It has been shown to reduce infarct size and induce autophagy in murine models of myocardial ischemia/reperfusion injury. This compound is valuable for research applications focused on cardiac health, autophagy pathways, and cellular stress responses. -
mTORC1 Inhibitor
ICSN3250 hydrochloride is a potent mTORC1 inhibitor that acts by binding to the FRB domain of mTOR, effectively displacing phosphatidic acid and reversing mTORC1 activation. This compound exhibits significant cytotoxicity in cancer cells at nanomolar concentrations via a caspase-independent cell death mechanism. By selectively inhibiting the mTORC1 pathway, ICSN3250 hydrochloride promotes autophagy and induces G0-G1 cell cycle arrest in cancer cells, making it a valuable tool for cancer research. -
mTORC1 Inhibitor
ICSN3250 is a selective mTORC1 inhibitor that operates by directly binding to the FRB domain of mTOR, effectively displacing phosphatidic acid and reversing mTORC1 activation. This compound demonstrates significant cytotoxicity in cancer cells at nanomolar concentrations via a caspase-independent cell death mechanism. Additionally, ICSN3250 specifically inhibits the mTORC1 pathway, promoting autophagy and inducing G0-G1 cell-cycle arrest. It is suitable for research applications focused on cancer biology and therapeutic exploration. -
PI3k/Akt/mTOR Inhibitor
D-87503 is a potent inhibitor of the PI3K/Akt/mTOR signaling pathway, exhibiting IC50 values of 62 nM for PI3K and 0.76 μM for Erk2. This compound effectively attenuates the activity of downstream substrates, including Akt and Rsk1, making it a valuable tool for studying cellular processes regulated by this pathway. D-87503 has applications in cancer research and investigates the role of PI3K signaling in various physiological conditions. -
AKT/mTOR Inhibitor
19-epi-Scholaricine is a potent AKT/mTOR inhibitor, classified as an orally active indole alkaloid. This compound downregulates profibrotic and apoptotic proteins, such as HRAS, HSP90AA1, and KDR, while upregulating the cell cycle regulator CDK2. Furthermore, 19-epi-Scholaricine inhibits ROS production and reduces inflammatory mediator release, leading to decreased podocyte apoptosis, renal inflammation, and oxidative stress. It is a valuable tool for research into chronic glomerulonephritis and membranous nephropathy. -
mTOR Inhibitor
Rapamycin-d3 is a deuterium-labeled analog of Rapamycin, a highly potent and selective inhibitor of the mechanistic target of rapamycin (mTOR), exhibiting an IC50 of 0.1 nM in HEK293 cells. It functions by binding to FKBP12, leading to allosteric inhibition of mTORC1. This compound is notable for its roles in autophagy activation and immunosuppression, making it valuable for various research applications including cancer biology, metabolic disorders, and studies of cellular growth and proliferation. -
PI3K/mTOR Inhibitor
Dactolisib hydrochloride is a potent dual inhibitor of class I phosphoinositide 3-kinases (PI3K) and the mammalian target of rapamycin (mTOR), specifically targeting p110α, p110γ, p110δ, and p110β with IC50 values of 4 nM, 5 nM, 7 nM, 75 nM, and 20.7 nM, respectively. This compound effectively inhibits both mTORC1 and mTORC2, making it a valuable tool for studying the PI3K/mTOR signaling pathway. Its applications include cancer research, drug development, and exploring therapeutic strategies for various diseases associated with dysregulated PI3K/mTOR signaling. -
mTOR/HDAC6 Inhibitor
mTOR/HDAC6-IN-1 is a potent dual inhibitor targeting mTOR and HDAC6, exhibiting IC50 values of 133.7 nM and 56 nM, respectively. This compound is known to induce significant autophagy and apoptosis while suppressing cell migration. It holds potential for research applications in triple-negative breast cancer (TNBC) studies, offering insights into the interplay between these critical pathways in cancer progression. -
mTOR Inhibitor
RapaLink-1 is a third-generation bivalent inhibitor targeting the mechanistic target of rapamycin (mTOR). By combining Rapamycin with MLN0128 through an inert linker, RapaLink-1 demonstrates superior efficacy in inhibiting both wild-type and mutant forms of mTOR compared to other inhibitors. This compound effectively crosses the blood-brain barrier, promoting durable mTORC1 inhibition via FKBP12 binding. Additionally, RapaLink-1 exhibits anticancer properties and may play an antithrombotic role in antiphospholipid syndrome by enhancing autophagy. -
mTOR Inhibitor/Autophagy Inducer
mTOR inhibitor-8 is a potent inhibitor of the mechanistic target of rapamycin (mTOR), functioning through the interaction with FKBP12. This compound effectively suppresses mTOR activity and induces autophagy in A549 human lung cancer cells. It is a valuable tool for studying mTOR signaling pathways and the role of autophagy in cancer research. -
mTOR/TEX264 Inhibitor
SI-W052 is a selective small-molecule inhibitor targeting mTOR and TEX264, with oral bioavailability and brain penetrance. It activates autophagy by inhibiting mTOR phosphorylation, while enhancing TEX264 expression to promote endoplasmic reticulum turnover. Additionally, SI-W052 suppresses LPS-induced release of inflammatory factors such as TNF-α and IL-6, making it a promising candidate for research into neuroinflammation associated with Alzheimer’s disease. -
Tyrosinase Inhibitor; Melanosome Inhibitor; mTORC1 Signaling Inhibitor
Decanoic acid is a tyrosinase inhibitor that also targets melanosomes and mTORC1 signaling pathways. It effectively reduces tyrosinase activity and inhibits melanosome maturation, while also suppressing c-Met phosphorylation and inducing apoptosis in hepatocellular carcinoma cells. This compound's ability to influence oncogenic protein expression makes it a valuable tool for research in melanoma, hepatocellular carcinoma, and epilepsy. Additionally, its brain-penetrant properties and non-competitive inhibition of AMPA receptors highlight its potential in neurological studies. -
mTOR
Dioctanoylphosphatidic acid sodium acts as a modulator of the mammalian target of rapamycin (mTOR) signaling pathway. This compound enhances phagocyte respiratory burst, serves as a precursor for diacylglycerol and lysophosphatidic acid, and improves the viability of gallbladder carcinoma cells when used in conjunction with histone deacetylase inhibitors (HDACIs). Its unique biosynthetic origins from glycerophospholipid highlight its relevance in cellular signaling research and cancer studies. -
mTORC1/glucose transporter Inhibitor
NV-5440 is an inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) and glucose transporters GLUT-1, GLUT-2, GLUT-3, and GLUT-4. This compound effectively inhibits glucose uptake in cells, providing valuable insights into glucose metabolism and its regulation. NV-5440 is useful for research applications involving cancer metabolism, diabetes, and other metabolic disorders where mTORC1 signaling and glucose transport play significant roles. -
FLNA Modulator
Simufilam hydrochloride is an orally active modulator of filamin A (FLNA) that targets neuronal signaling pathways. This compound restores NMDAR signaling and Arc expression while inhibiting dysregulated mTOR activity. Additionally, it enhances insulin sensitivity and mitigates Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam hydrochloride is applicable in research related to Alzheimer's disease, particularly in understanding the underlying mechanisms of neurodegeneration. -
FLNA Modulator
Simufilam is an orally active modulator of filamin A (FLNA) that restores NMDA receptor (NMDAR) signaling and Arc expression. It effectively inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, which results in improved insulin sensitivity and a reduction in Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. This compound is particularly valuable for research applications focused on Alzheimer's disease and related neurodegenerative disorders. -
mTORC1/S6K1 Inhibitor
Coronarin A is a natural compound that functions as an inhibitor of mTORC1 and S6K1, enhancing IRS1 activity. This compound exhibits anti-inflammatory properties and is relevant for research into type 2 diabetes mellitus. Its modulation of key signaling pathways makes Coronarin A a valuable tool for studying metabolic disorders and inflammation-related conditions. -
Nrf2/AMPK/mTOR Activator
Hydroxycitric acid is an orally active compound that serves as a multifunctional activator of Nrf2, AMPK, and mTOR pathways. It enhances the expression of antioxidant enzymes, such as superoxide dismutase, and increases glutathione levels, thereby mitigating oxidative stress and ferroptosis, particularly in renal tubular epithelial cells. Additionally, hydroxycitric acid induces cell cycle arrest in cancer cells and promotes DNA fragmentation through modulation of the AMPK and mTORC1/S6K signaling pathways. This compound is valuable for research in oxidative stress, cancer biology, and metabolic regulation. -
mTORC2 Inhibitor
JR-AB2-011 is a selective inhibitor of the mTORC2 complex, exhibiting an IC50 value of 0.36 μM. This compound disrupts the association between Rictor and mTOR (Ki: 0.19 μM), leading to reduced phosphorylation of Akt and decreased MMP2 activity. Consequently, JR-AB2-011 inhibits the migratory and invasive capabilities of tumor cells while also triggering non-apoptotic cell death. It serves as a valuable tool for research into cancer treatment and the regulation of cellular signaling pathways. -
mTORC1 Inhibitor
RMC-5552 is a potent and selective inhibitor of the mTORC1 pathway. It effectively inhibits the phosphorylation of S6K and 4EBP1 with IC50 values of 0.14 nM and 0.48 nM, respectively. RMC-5552 demonstrates significantly lower inhibition of AKT (IC50 of 19 nM), conferring a selectivity ratio for mTORC1 over mTORC2 of nearly 40-fold. This compound exhibits anti-cancer activity, making it a valuable tool for cancer research and therapeutic development targeting mTOR signaling. -
Rheb/mTORC1 Inhibitor
Rheb inhibitor NR1 is a selective Rheb/mTORC1 inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. This compound directly binds to the switch II domain of Rheb, effectively inhibiting the activation of the mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 attenuates phosphorylation of T389pS6K1 while enhancing phosphorylation of S473pAKT in a dose-dependent manner, with no effect on mTORC2 activity. It serves as a valuable tool for investigating the mTOR signaling pathway and its implications in various diseases. -
PIP4K2C-mTOR Activator
C24-Ceramide is a competitive binding agonist of PIP4K2C, a key regulator of the mTOR signaling pathway. This compound facilitates cellular processes such as enhanced keratinocyte proliferation and migration, thereby promoting skin wound healing. Moreover, C24-Ceramide has been implicated in the proliferation and metastasis of gallbladder cancer cells, indicating its potential as a therapeutic target. Additionally, C24-Ceramide levels in serum may serve as a diagnostic marker for gallbladder cancer. -
mTORC1 Activator
Mefluleucine hydrochloride is a selective and orally active activator of mTORC1, functioning primarily through its interaction with Sestrin2. This leucine analog plays a critical role in neurobiology and has been utilized in research studies focused on antidepressant mechanisms. Its distinct properties make it a valuable tool for investigating mTORC1 signaling pathways and their implications in mood disorders. -
mTORC1-Selective Inhibitor
RMC-6272 is a bi-steric inhibitor selectively targeting mTORC1. It demonstrates potent inhibition of mTORC1 with over 10-fold selectivity compared to mTORC2, outperforming Rapamycin in its ability to inhibit mTORC1 and induce cell death in TSC2 null tumors. This compound is valuable for research applications focusing on cancer biology and therapeutic strategies targeting the mTOR signaling pathway. -
Dual PI3K/mTOR Inhibitor
PKI-179 is a highly effective dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ, and mTOR, respectively. It demonstrates significant activity against E545K and H1047R mutant isoforms, with IC50 values of 14 nM and 11 nM. PKI-179 is utilized in cancer research due to its proven anti-tumor efficacy in vivo, making it a valuable tool for investigating the PI3K/mTOR signaling pathway in various cancer models. -
mTOR Inhibitor
PQR626 is a selective mTOR inhibitor that demonstrates potent activity with an IC50 of 5 nM and a Ki of 3.6 nM. This orally active compound is designed for effective brain penetration, making it suitable for investigating neurological disorders. Research applications include studying the role of mTOR in neurodegenerative diseases and evaluating potential therapeutic strategies targeting this pathway. -
mTORC1/mTORC2 Inhibitor
MTI-31 is a potent inhibitor of mTORC1 and mTORC2, demonstrating high selectivity for mTOR with a Kd of 0.20 nM and over 5,000-fold selectivity against PIK3CA, PIK3CB, and PIK3G. It exhibits an IC50 of 39 nM in the LANCE assay for mTOR substrate phosphorylation in the presence of 100 μM ATP. This compound is valuable for research into breast cancer and other diseases involving aberrant mTOR signaling pathways. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-4 is a potent orally active pan-class I PI3K/mTOR inhibitor. It demonstrates enzymatic inhibition across PI3Kα, PI3Kγ, PI3Kδ, and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM, and 13.85 nM, respectively. This reagent is primarily utilized in cancer research to investigate the role of the PI3K/mTOR signaling pathway in tumorigenesis and therapeutic responses. -
mTOR Inhibitor
WYE-23 is a selective mTOR inhibitor with a reported IC50 of 0.45 nM against mTOR and 661 nM against PI3Kα. This compound exhibits significant antitumor activity, making it a valuable reagent for cancer research. It is particularly useful for studies investigating the role of mTOR signaling in tumorigenesis and therapeutic interventions targeting this pathway. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-11 is a potent oral inhibitor of the PI3K/mTOR signaling pathway, exhibiting IC50 values of 3.5 nM, 4.6 nM, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR, respectively. This compound effectively impairs the phosphorylation of AKT and S6 proteins, thereby modulating critical cellular processes. PI3K/mTOR Inhibitor-11 is valuable for cancer research, offering insights into therapeutic strategies targeting aberrant signaling in tumors. -
mTORC1 Inhibitor
RMC-4627 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1), a key regulator of cell growth and proliferation. This compound has been shown to activate 4EBP1, leading to the downregulation of protein synthesis and subsequently inhibiting tumor growth. RMC-4627 is valuable for research applications focused on cancer biology and the elucidation of mTOR signaling pathways. -
TMBIM6 Antagonist
TMBIM6 antagonist-1 selectively inhibits TMBIM6, disrupting its interaction with mTORC2, and thereby decreasing mTORC2 activity. This compound also modulates TMBIM6-mediated calcium leakage, which is relevant for investigating calcium signaling pathways. TMBIM6 antagonist-1 serves as a valuable tool for research on cellular signaling and the role of TMBIM6 in various biological processes. -
mTOR Complex 1 Inhibitor
WRX606 is a selective inhibitor of the mTOR complex 1 (mTORC1), which effectively disrupts the phosphorylation of key mTORC1 substrates, including S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E binding protein (4E-BP1), with IC50 values of 10 nM and 0.27 μM, respectively. This compound demonstrates significant antitumor activity by suppressing tumor growth in mouse models without promoting metastasis. WRX606 is a valuable tool for research focused on exploring therapeutic strategies against cancer through mTORC1 inhibition. -
mTOR Inhibitor
mTOR inhibitor WYE-28 selectively targets the mammalian target of rapamycin (mTOR), exhibiting an IC50 of 0.08 nM. Additionally, it inhibits PI3Kα with an IC50 of 6 nM, demonstrating its potential for broader applications in cancer therapy and metabolic research. WYE-28 has a metabolic half-life (T1/2) of 13 minutes in nude mouse microsomes, making it a valuable reagent for studying mTOR signaling pathways and their implications in disease models. -
mTOR Inhibitor
(32-Carbonyl)-RMC-5552 is a potent inhibitor of the mechanistic target of rapamycin (mTOR), effectively blocking mTORC1 and mTORC2 signaling pathways. This compound impedes the phosphorylation of key substrates including p-P70S6K-(T389), p-4E-BP1-(T37/36), and p-AKT1/2/3-(S473), with pIC50 values greater than 9 for the first two and between 8 and 9 for the latter. (32-Carbonyl)-RMC-5552 is valuable for studies investigating mTOR-related cellular processes and the development of therapies targeting mTOR in various diseases. -
mTORC1/2 Inhibitor
AZD3147 is a potent, orally bioavailable dual inhibitor of mTORC1 and mTORC2, exhibiting an IC50 value of 1.5 nM. This compound selectively targets both complexes, while also having a specific inhibitory effect on PI3K. AZD3147 is primarily utilized in research related to cancer therapeutics and metabolic disorders, where modulation of the mTOR signaling pathway is of significant interest. -
mTOR Inhibitor
WYE-687 dihydrochloride is an ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR), demonstrating an IC50 of 7 nM. This compound effectively inhibits the activation of both mTORC1 and mTORC2, making it a valuable tool for studying mTOR signaling pathways. Additionally, WYE-687 modulates PI3Kα and PI3Kγ activity with IC50 values of 81 nM and 3.11 μM, respectively, supporting its role in cancer and metabolic research. -
PI3K/mTOR Inhibitor
DS-7423 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 15.6 nM for PI3Kα and 34.9 nM for mTOR. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research into cancer biology and potential therapeutic strategies. Its ability to inhibit key signaling pathways involved in cell growth and survival positions DS-7423 as a promising candidate for further exploration in oncology studies. -
PI3K/mTOR Inhibitor
PI3K-IN-37 is a potent inhibitor of the PI3K family, specifically targeting PI3K α, β, and δ isoforms with IC50 values of 6, 8, and 4 nM, respectively. Additionally, PI3K-IN-37 demonstrates strong inhibition of mTOR with an IC50 of 4 nM. This compound is valuable for research applications involving cancer biology, metabolic disorders, and signaling pathways related to cell growth and survival. -
PI3Kα/mTOR Kinase Inhibitor
PI3K-IN-22 is a potent dual inhibitor of the PI3Kα and mTOR kinases, with IC50 values of 0.9 nM and 0.6 nM, respectively. This compound exhibits substantial biological activity, making it valuable for investigating the roles of these pathways in cancer research. PI3K-IN-22 can facilitate the study of tumor growth and response to therapy, contributing to the understanding of oncogenic signaling and potential treatment strategies. -
Dual PI3K/mTOR Inhibitor
PKI-179 hydrochloride is a potent dual inhibitor of the PI3K and mTOR signaling pathways, demonstrating IC50 values of 8 nM for PI3K-α, 24 nM for PI3K-β, 74 nM for PI3K-γ, 77 nM for PI3K-δ, and 0.42 nM for mTOR. This compound is effective against mutant variants E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride has been shown to exhibit significant anti-tumor activity in vivo, making it a valuable tool for cancer research and therapeutic development targeting PI3K/mTOR pathways. -
PI3K/mTOR Inhibitor
SN32976 is a potent and selective inhibitor of class I phosphoinositide 3-kinases (PI3K) and mTOR, exhibiting IC50 values of 15.1 nM for PI3Kα, 461 nM for PI3Kβ, 110 nM for PI3Kγ, 134 nM for PI3Kδ, and 194 nM for mTOR. This compound demonstrates significant selectivity against a wide panel of 442 kinases. SN32976 is primarily utilized in cancer research, showcasing notable anticancer activity that makes it a valuable tool for studying PI3K/mTOR pathway modulation. -
mTOR Inhibitor
MHY-1685 is a novel inhibitor of the mammalian target of rapamycin (mTOR), a key regulator of cell growth and metabolism. This compound demonstrates significant potential in promoting human cardiac stem cell (hCSC)-based myocardial regeneration. Its efficacy in modulating the mTOR pathway makes MHY-1685 a valuable tool for researchers investigating cardiac repair mechanisms and therapies. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-13 sodium is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mTOR kinase, demonstrating oral bioavailability. This compound exhibits significant biological activity in the modulation of cellular growth and metabolism, making it a valuable tool in research related to sexual dysfunction, solid tumors, and idiopathic pulmonary fibrosis (IPF). Its dual inhibition profile presents opportunities for therapeutic exploration in various disease contexts. -
PI3K/mTOR inhibitor
PI3K-IN-18 is a potent inhibitor of the PI3K/mTOR signaling pathway, selectively targeting PI3K-α and mTOR with IC50 values of 41 nM and 49 nM, respectively. This compound exhibits significant biological activity by disrupting key signaling processes involved in cell growth and proliferation. PI3K-IN-18 is valuable for research applications focused on cancer biology, metabolism, and therapeutic strategies targeting the PI3K/mTOR axis. -
mTORC1/2 Inhibitor
Dihydroevocarpine is a selective inhibitor of mTORC1 and mTORC2, exhibiting potent cytotoxic effects in acute myeloid leukemia cells. By effectively suppressing mTORC1/2 activity, it disrupts critical signaling pathways involved in cell proliferation and survival. This compound is valuable for research focused on cancer biology and the development of targeted therapies for hematological malignancies.
